Invivyd, Inc. (NASDAQ:IVVD) Stock Has Average Target Price of $10.00 According to Analysts

Invivyd, Inc. (NASDAQ:IVVD) has received a consensus recommendation of “Hold” from the six analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating on shares of Invivyd in a report on Tuesday, September 29th. BTIG Research reiterated a “buy” rating on shares of Invivyd in a report on Monday, September 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Invivyd in a report on Thursday, August 27th. Finally, Weiss Ratings upgraded Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 8th.

Invivyd Stock Down 3.7%

Shares of IVVD opened at $0.57 on Wednesday. The company has a market capitalization of $169.31 million, a price-to-earnings ratio of -1.74 and a beta of 1.20. Invivyd has a 52 week low of $0.53 and a 52 week high of $3.07. The stock’s 50-day moving average price is $0.74 and its 200-day moving average price is $1.11.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The firm had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. As a group, equities analysts anticipate that Invivyd will post -0.51 EPS for the current fiscal year.

Insider Buying and Selling at Invivyd

In related news, insider Jill Andersen sold 30,706 shares of Invivyd stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total value of $25,793.04. Following the completion of the transaction, the insider directly owned 283,774 shares in the company, valued at approximately $238,370.16. This trade represents a 9.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 228,024 shares of company stock worth $176,540 over the last 90 days. 12.25% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Invivyd

A number of large investors have recently modified their holdings of IVVD. Chicago Partners Investment Group LLC purchased a new position in shares of Invivyd in the 1st quarter valued at about $25,000. Bank of New York Mellon Corp increased its position in Invivyd by 54.3% in the 1st quarter. Bank of New York Mellon Corp now owns 27,184 shares of the company’s stock valued at $35,000 after acquiring an additional 9,568 shares during the period. SummitTX Capital L.P. acquired a new position in shares of Invivyd in the first quarter valued at approximately $37,000. Rangeley Capital LLC purchased a new position in Invivyd during the 1st quarter worth $58,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Invivyd in the second quarter valued at about $52,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc. is a biotechnology company focused on developing antibody-based medicines designed to prevent and treat infectious diseases. The company uses its antibody discovery and engineering technologies to create broadly neutralizing antibodies intended to remain effective as viruses evolve. Invivyd’s lead product is pemivibart, marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration granted pemivibart an Emergency Use Authorization in 2024 for pre-exposure prophylaxis against COVID-19 in certain individuals who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to vaccination.